NV Therapeutics
Berkeley, US · Founded 2024 · Delaware corporation · 8 employees on LinkedIn · 1 known investors
Find your way into NV Therapeutics
798 people in our graph share verified history with the NV Therapeutics team — schools, employers, funds. One of them is your warm intro.
Tobi Cokerunlockedknows Dima Kuzmin · together at Kauffman Fellows (overlapped)
×10knows the team · via Kauffman Fellows
knows the team · via University of Oxford
NV Therapeutics develops non-viral gene therapies designed to be safe, effective, and scalable. The company targets a new generation of genetic treatments for disease.
Founders & leadership
NV Therapeutics was founded in 2024 by Jake Lamson, Adrian Thrasher, Donald Kohn, Giorgia Santilli, and Dima Kuzmin.
JL
Jake LamsonCo-Founder & Director of Synthetic Biology
AT
Adrian ThrasherScientific Co-Founder & Advisor
DK
Donald KohnScientific Co-Founder & Advisor
GS
Giorgia SantilliScientific Co-Founder & Advisor
DK
Dima Kuzminin𝕏Board Director & Scientific Co-FounderHe previously founded 4BIO Capital, a venture fund he built from 2014 to Fund III, and spent years in academic research spanning structural biology, neurochemistry, systems neuroscience, brain-computer interfaces, and gene therapy.
KH
Kevin HoldeninChief Executive OfficerKevin Holden holds a PhD in molecular microbiology and brings over 15 years of industrial biotechnology experience in genome engineering and synthetic biology, with expertise in high-throughput automation and technology development. He is CEO and co-founder of NV Therapeutics, which develops non-viral gene therapies.
Board
AK
Audrey KozlovBoard director
DD
Daniel DeverScientific Co-Founder, Advisor & Board Member
DK
Investors · 1
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2024
▶$3MraisedMar 2025 · 1 investors · OtherRule 506(b)
▶$3MraisedMar 2025 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Audrey KozlovDirector
- Daniel DeverDirector
- Kevin HoldenExecutive Officer, Director, Promoter
- Dmitry KuzminDirector
- Offering amount
- $7.5M
- Amount sold
- $3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does NV Therapeutics do?
- NV Therapeutics develops non-viral gene therapies designed to be safe, effective, and scalable. The company targets a new generation of genetic treatments for disease.
- Who founded NV Therapeutics?
- NV Therapeutics was founded by Jake Lamson, Adrian Thrasher, Donald Kohn, Giorgia Santilli, Dima Kuzmin in 2024.
- Who are NV Therapeutics's investors?
- NV Therapeutics's investors include 4Bio Ventures.
- How much funding has NV Therapeutics raised?
- NV Therapeutics has disclosed $3M raised across 1 round.
- Where is NV Therapeutics headquartered?
- NV Therapeutics is headquartered in Berkeley, US.